Marina Stolina
Overview
Explore the profile of Marina Stolina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
3520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Hu L, Lei Y, Stolina M, Homann O, Wang S, et al.
Cell Rep
. 2023 Aug;
42(8):112952.
PMID: 37556324
Obesity and type 2 diabetes (T2D) remain major global healthcare challenges, and developing therapeutics necessitates using nonhuman primate models. Here, we present a transcriptomic and proteomic atlas of all the...
2.
Florio M, Kostenuik P, Stolina M, Asuncion F, Grisanti M, Ke H, et al.
J Bone Joint Surg Am
. 2023 May;
105(15):1145-1155.
PMID: 37159527
Background: Fracture repair involves the reactivation of developmental signaling cascades, including Wnt signaling that stimulates bone formation and bone regeneration. Rodent data indicate that dual inhibition of the Wnt signaling...
3.
Gotts J, Maishan M, Chun L, Fang X, Han C, Chiueh V, et al.
Physiol Rep
. 2021 Nov;
9(21):e15081.
PMID: 34755490
Influenza remains a major cause of death and disability with limited treatment options. Studies of acute lung injury have identified angiopoietin-2 (Ang-2) as a key prognostic marker and a potential...
4.
Lu S, Chen M, Atangan L, Killion E, Komorowski R, Cheng Y, et al.
Cell Rep Med
. 2021 Jun;
2(5):100263.
PMID: 34095876
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate glucose and energy homeostasis. Targeting both pathways with GIP receptor (GIPR) antagonist antibody (GIPR-Ab) and GLP-1 receptor (GLP-1R) agonist, by generating...
5.
Luo X, Yin J, Dwyer D, Yamawaki T, Zhou H, Ge H, et al.
Sci Rep
. 2021 Jun;
11(1):11839.
PMID: 34088950
Heart failure with reduced ejection fraction (HFrEF) constitutes 50% of HF hospitalizations and is characterized by high rates of mortality. To explore the underlying mechanisms of HFrEF etiology and progression,...
6.
Darkow E, Nguyen T, Stolina M, Kari F, Schmidt C, Wiedmann F, et al.
Front Physiol
. 2021 Apr;
12:650964.
PMID: 33868017
In search of more efficacious and safe pharmacological treatments for atrial fibrillation (AF), atria-selective antiarrhythmic agents have been promoted that target ion channels principally expressed in the atria. This concept...
7.
Whyte M, Aronson J, McAlister W, Weinstein R, Wenkert D, Clements K, et al.
Bone
. 2020 Dec;
145:115835.
PMID: 33360005
In 2003, we briefly reported the remarkable osteopathy of a 12-year-old boy who at age two months began fracturing his limbs with subsequent hyperplastic callus formation and expansion and fusion...
8.
Hahn V, Knutsdottir H, Luo X, Bedi K, Margulies K, Haldar S, et al.
Circulation
. 2020 Oct;
143(2):120-134.
PMID: 33118835
Background: Heart failure (HF) with preserved ejection fraction (HFpEF) constitutes half of all HF but lacks effective therapy. Understanding of its myocardial biology remains limited because of a paucity of...
9.
Stolina M, Luo X, Dwyer D, Han C, Chen R, Zhang Y, et al.
PLoS One
. 2020 Aug;
15(8):e0231234.
PMID: 32804947
Cardiometabolic syndrome has become a global health issue. Heart failure is a common comorbidity of cardiometabolic syndrome. Successful drug development to prevent cardiometabolic syndrome and associated comorbidities requires preclinical models...
10.
Turk J, Deaton A, Yin J, Stolina M, Felx M, Boyd G, et al.
Regul Toxicol Pharmacol
. 2020 Jun;
115:104697.
PMID: 32590049
Romosozumab (EVENITY™ [romosozumab-aqqg in the US]) is a humanized monoclonal antibody that inhibits sclerostin and has been approved in several countries for the treatment of osteoporosis in postmenopausal women at...